[go: up one dir, main page]

MX2020009649A - Anticuerpos monoclonales contra bcma. - Google Patents

Anticuerpos monoclonales contra bcma.

Info

Publication number
MX2020009649A
MX2020009649A MX2020009649A MX2020009649A MX2020009649A MX 2020009649 A MX2020009649 A MX 2020009649A MX 2020009649 A MX2020009649 A MX 2020009649A MX 2020009649 A MX2020009649 A MX 2020009649A MX 2020009649 A MX2020009649 A MX 2020009649A
Authority
MX
Mexico
Prior art keywords
antibodies against
monoclonal antibodies
against bcma
bcma
manufacture
Prior art date
Application number
MX2020009649A
Other languages
English (en)
Inventor
Marina Bacac
Pablo Umana
Camille Delon
Samuel Moser
Minh Diem Vu
Klaus Strein
Oliver Ast
Lydia Jasmin Duerner
Anne Freimoser-Grundschober
Christian Klein
Ekkehard Moessner
Tina Weinzierl
Original Assignee
Engmab Sarl
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Engmab Sarl filed Critical Engmab Sarl
Publication of MX2020009649A publication Critical patent/MX2020009649A/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/46—Hybrid immunoglobulins
    • C07K16/468—Immunoglobulins having two or more different antigen binding sites, e.g. multifunctional antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2878—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the NGF-receptor/TNF-receptor superfamily, e.g. CD27, CD30, CD40, CD95
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/39558—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against tumor tissues, cells, antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C07K16/2809—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against the T-cell receptor (TcR)-CD3 complex
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/30—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/46—Hybrid immunoglobulins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/31—Immunoglobulins specific features characterized by aspects of specificity or valency multispecific
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/60—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments
    • C07K2317/66—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments comprising a swap of domains, e.g. CH3-CH2, VH-CL or VL-CH1
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/70—Fusion polypeptide containing domain for protein-protein interaction

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Oncology (AREA)
  • Engineering & Computer Science (AREA)
  • Hematology (AREA)
  • Biomedical Technology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Epidemiology (AREA)
  • Cell Biology (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)

Abstract

La presente invención se refiere a nuevos anticuerpos contra BCMA, su manufactura y uso.
MX2020009649A 2015-08-03 2018-02-01 Anticuerpos monoclonales contra bcma. MX2020009649A (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
EP15179549 2015-08-03

Publications (1)

Publication Number Publication Date
MX2020009649A true MX2020009649A (es) 2020-10-08

Family

ID=53776451

Family Applications (2)

Application Number Title Priority Date Filing Date
MX2018001398A MX377710B (es) 2015-08-03 2016-08-03 Anticuerpos monoclonales contra bcma.
MX2020009649A MX2020009649A (es) 2015-08-03 2018-02-01 Anticuerpos monoclonales contra bcma.

Family Applications Before (1)

Application Number Title Priority Date Filing Date
MX2018001398A MX377710B (es) 2015-08-03 2016-08-03 Anticuerpos monoclonales contra bcma.

Country Status (29)

Country Link
US (3) US10683369B2 (es)
EP (2) EP3331910B1 (es)
JP (2) JP6682632B2 (es)
KR (1) KR102717307B1 (es)
CN (1) CN108350073B (es)
AU (1) AU2016302881B2 (es)
BR (1) BR112018001955B1 (es)
CA (1) CA2992797A1 (es)
CL (3) CL2018000281A1 (es)
CO (1) CO2018001149A2 (es)
CY (1) CY1122804T1 (es)
DK (1) DK3331910T3 (es)
EA (2) EA202092435A3 (es)
EC (1) ECSP18007905A (es)
ES (1) ES2777602T3 (es)
HR (1) HRP20200390T1 (es)
HU (1) HUE048939T2 (es)
IL (1) IL257233B (es)
LT (1) LT3331910T (es)
MX (2) MX377710B (es)
PL (1) PL3331910T3 (es)
PT (1) PT3331910T (es)
RS (1) RS60030B1 (es)
SA (1) SA518390854B1 (es)
SG (1) SG10202007177XA (es)
SI (1) SI3331910T1 (es)
SM (1) SMT202000139T1 (es)
WO (1) WO2017021450A1 (es)
ZA (1) ZA201800435B (es)

Families Citing this family (105)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
MX356947B (es) 2011-08-23 2018-06-20 Roche Glycart Ag Anticuerpos bioespecíficos específicos para antígenos que activan células t y un antígeno tumoral y métodos de uso.
CA2879768A1 (en) 2012-10-08 2014-04-17 Roche Glycart Ag Fc-free antibodies comprising two fab-fragments and methods of use
KR102282761B1 (ko) 2013-02-26 2021-07-30 로슈 글리카트 아게 이중특이적 t 세포 활성화 항원 결합 분자
PE20211533A1 (es) 2014-08-04 2021-08-16 Hoffmann La Roche Moleculas biespecificas de unon a antigeno activadoras de celulas t
US11952421B2 (en) 2014-10-09 2024-04-09 Bristol-Myers Squibb Company Bispecific antibodies against CD3EPSILON and ROR1
DK3221355T3 (da) 2014-11-20 2020-12-07 Hoffmann La Roche Kombinationsbehandling med T-celleaktiverende bispecifikke antigenbindende molekyler CD3 og folatreceptor 1 (FolR1) samt PD-1-aksebindende antagonister
MY184889A (en) 2014-11-20 2021-04-29 Hoffmann La Roche T cell activating bispecific antigen binding molecules
RS60615B1 (sr) 2014-11-20 2020-08-31 Hoffmann La Roche Zajednički laki lanci i postupci upotrebe
CN111234027A (zh) 2015-05-21 2020-06-05 哈普恩治疗公司 三特异性结合蛋白质及使用方法
JP7044700B2 (ja) 2015-10-02 2022-03-30 エフ・ホフマン－ラ・ロシュ・アクチェンゲゼルシャフト 二重特異性抗ｃｅａｘｃｄ３ ｔ細胞活性化抗原結合分子
EP3387015B1 (en) 2015-12-09 2021-10-27 F. Hoffmann-La Roche AG Type ii anti-cd20 antibody for reducing formation of anti-drug antibodies
IL259588B2 (en) 2016-01-08 2023-09-01 Hoffmann La Roche Methods for the treatment of cea-positive cancer using pd-1 spindle-binding antagonists and bispecific antibodies against anti-cea and anti-cd3
US20170233484A1 (en) 2016-02-17 2017-08-17 Seattle Genetics, Inc. Bcma antibodies and use of same to treat cancer and immunological disorders
FI3433280T3 (fi) 2016-03-22 2023-06-06 Hoffmann La Roche Proteaasin aktivoimia t-solubispesifisiä molekyylejä
JP7022123B2 (ja) 2016-09-30 2022-02-17 エフ・ホフマン－ラ・ロシュ・アクチェンゲゼルシャフト Ｃｄ３に対する二重特異性抗体
KR102687833B1 (ko) * 2016-11-02 2024-07-24 브리스톨-마이어스 스큅 컴퍼니 다발성 골수종 치료를 위한 bcma 및 cd3에 대응하는 이중 특이적 항체 및 면역학적 약물의 복합용도
CN110582509A (zh) 2017-01-31 2019-12-17 诺华股份有限公司 使用具有多特异性的嵌合t细胞受体蛋白治疗癌症
WO2018201056A1 (en) 2017-04-28 2018-11-01 Novartis Ag Cells expressing a bcma-targeting chimeric antigen receptor, and combination therapy with a gamma secretase inhibitor
US20200179511A1 (en) 2017-04-28 2020-06-11 Novartis Ag Bcma-targeting agent, and combination therapy with a gamma secretase inhibitor
WO2019035938A1 (en) 2017-08-16 2019-02-21 Elstar Therapeutics, Inc. MULTISPECIFIC MOLECULES BINDING TO BCMA AND USES THEREOF
CN111094353A (zh) 2017-09-14 2020-05-01 葛兰素史密斯克莱知识产权发展有限公司 用于癌症的组合治疗
JP2020533383A (ja) 2017-09-14 2020-11-19 グラクソスミスクライン、インテレクチュアル、プロパティー、ディベロップメント、リミテッドＧｌａｘｏｓｍｉｔｈｋｌｉｎｅ Ｉｎｔｅｌｌｅｃｔｕａｌ Ｐｒｏｐｅｒｔｙ Ｄｅｖｅｌｏｐｍｅｎｔ Ｌｉｍｉｔｅｄ 癌の組合せ治療
EP3694878A1 (en) * 2017-09-14 2020-08-19 GlaxoSmithKline Intellectual Property Development Limited Combination treatment for cancer
CA3078969A1 (en) 2017-10-13 2019-04-18 Harpoon Therapeutics, Inc. Trispecific proteins and methods of use
IL315737A (en) * 2017-10-13 2024-11-01 Harpoon Therapeutics Inc B-cell maturation antigen-binding proteins
AU2018351050B2 (en) 2017-10-18 2025-09-18 Novartis Ag Compositions and methods for selective protein degradation
JP2021502979A (ja) 2017-11-15 2021-02-04 ノバルティス アーゲー Ｂｃｍａターゲティングキメラ抗原受容体、ｃｄ１９ターゲティングキメラ抗原受容体及び併用療法
RU2020121458A (ru) 2017-11-30 2021-12-30 Новартис Аг Химерный антигенный рецептор, нацеливающийся на bcma, и его пути применения
US20200368268A1 (en) 2018-01-08 2020-11-26 Novartis Ag Immune-enhancing rnas for combination with chimeric antigen receptor therapy
US12247060B2 (en) 2018-01-09 2025-03-11 Marengo Therapeutics, Inc. Calreticulin binding constructs and engineered T cells for the treatment of diseases
CA3090249A1 (en) 2018-01-31 2019-08-08 Novartis Ag Combination therapy using a chimeric antigen receptor
TWI800854B (zh) * 2018-02-01 2023-05-01 大陸商信達生物製藥（蘇州）有限公司 全人源的抗ｂ細胞成熟抗原（ｂｃｍａ）單鏈抗體及其應用
CN111712261B (zh) 2018-02-08 2024-08-09 豪夫迈·罗氏有限公司 双特异性抗原结合分子和使用方法
EP3752203A1 (en) 2018-02-13 2020-12-23 Novartis AG Chimeric antigen receptor therapy in combination with il-15r and il15
SG11202007495SA (en) 2018-02-21 2020-09-29 Celgene Corp Bcma-binding antibodies and uses thereof
EP3765517A1 (en) 2018-03-14 2021-01-20 Elstar Therapeutics, Inc. Multifunctional molecules that bind to calreticulin and uses thereof
EP3774901A1 (en) * 2018-03-26 2021-02-17 Sutro Biopharma, Inc. Anti-bcma receptor antibodies, compositions comprising anti bcma receptor antibodies and methods of making and using anti-bcma antibodies
EP3774885A2 (en) 2018-03-30 2021-02-17 Merus N.V. Multivalent antibody
MX2020012485A (es) * 2018-05-23 2021-04-28 Celgene Corp Compuestos antiproliferativos y anticuerpo biespecifico contra bcma y cd3 para uso combinado.
CA3098420A1 (en) 2018-06-01 2019-12-05 Novartis Ag Binding molecules against bcma and uses thereof
WO2020010250A2 (en) 2018-07-03 2020-01-09 Elstar Therapeutics, Inc. Anti-tcr antibody molecules and uses thereof
BR112021002072A2 (pt) 2018-08-08 2021-06-01 Dragonfly Therapeutics, Inc. proteínas de ligação multiespecíficas que se ligam a bcma, nkg2d e cd16, e métodos de uso
CN109134665B (zh) * 2018-08-24 2021-06-11 上海先博生物科技有限公司 一种基于单域抗体的bcma嵌合抗原受体及应用
SG11202101825QA (en) 2018-08-31 2021-03-30 Novartis Ag Methods of making chimeric antigen receptor-expressing cells
US20210171909A1 (en) 2018-08-31 2021-06-10 Novartis Ag Methods of making chimeric antigen receptor?expressing cells
WO2020061482A1 (en) 2018-09-21 2020-03-26 Harpoon Therapeutics, Inc. Egfr binding proteins and methods of use
SG11202103022WA (en) 2018-09-25 2021-04-29 Harpoon Therapeutics Inc Dll3 binding proteins and methods of use
CN109503716B (zh) * 2018-10-08 2021-04-27 浙江生研生物科技有限公司 一种双特异性嵌合抗原受体分子及其在肿瘤治疗上的应用
BR112021008055A2 (pt) 2018-10-31 2021-08-10 Glaxosmithkline Intellectual Property Development Limited métodos para determinar o prognóstico de câncer em um paciente, para prever uma resposta do paciente ao tratamento com uma proteína de ligação ao antígeno bcma, para selecionar a dose de uma proteína de ligação ao antígeno bcma e para diagnosticar câncer, composições farmacêuticas, kit e uso de uma proteína de ligação ao antígeno bcma para tratar câncer
WO2020089437A1 (en) 2018-10-31 2020-05-07 Engmab Sàrl Combination therapy
MA54079A (fr) 2018-11-01 2021-09-08 Juno Therapeutics Inc Récepteurs antigéniques chimériques spécifiques du gprc5d (élément d du groupe 5 de classe c des récepteurs couplés à la protéine g)
CN109678961A (zh) * 2019-01-15 2019-04-26 深圳市南科生物工程有限公司 一种基于bmca纳米抗体序列的嵌合抗原受体的构建方法及其应用
AU2020224681A1 (en) 2019-02-21 2021-09-16 Marengo Therapeutics, Inc. Antibody molecules that bind to NKp30 and uses thereof
SG11202109061YA (en) 2019-02-21 2021-09-29 Marengo Therapeutics Inc Multifunctional molecules that bind to t cell related cancer cells and uses thereof
WO2020176397A1 (en) 2019-02-25 2020-09-03 Novartis Ag Mesoporous silica particles compositions for viral delivery
WO2020191316A1 (en) 2019-03-21 2020-09-24 Novartis Ag Car-t cell therapies with enhanced efficacy
WO2020210678A1 (en) 2019-04-12 2020-10-15 Novartis Ag Methods of making chimeric antigen receptor-expressing cells
US20220251152A1 (en) 2019-04-24 2022-08-11 Novartis Ag Compositions and methods for selective protein degradation
WO2020219978A1 (en) 2019-04-25 2020-10-29 Celgene Corporation Bcma/cd3 bispecific trivalent t-cell engaging (tce) antibodies and their use to treat hematological malignancies
US12221481B2 (en) 2019-05-21 2025-02-11 Novartis Ag CD19 binding molecules and uses thereof
CN110229232B (zh) * 2019-06-19 2020-05-19 北京智仁美博生物科技有限公司 双特异性抗体及其用途
CA3146341A1 (en) * 2019-07-30 2021-02-04 Aaron L. Kurtzman Bispecific anti lrrc15 and cd3epsilun antibudies
CN112585168B (zh) * 2019-07-30 2022-04-15 上海翰森生物医药科技有限公司 抗bcma抗体、其抗原结合片段及其医药用途
PH12022550277A1 (en) 2019-08-06 2022-11-21 Glaxosmithkline Ip Dev Ltd Biopharmacuetical compositions and related methods
CN112574308A (zh) * 2019-09-30 2021-03-30 和铂医药(苏州)有限公司 靶向bcma的抗体、双特异性抗体及其用途
US20240052048A1 (en) * 2019-10-10 2024-02-15 Suzhou Qin Pharmaceuticals Co., Ltd. Humanized monoclonal antibody targeting bcma and having human monkey cross-reactivity
KR20220093141A (ko) * 2019-11-05 2022-07-05 브리스톨-마이어스 스큅 컴퍼니 Bcma 및 cd3에 대한 항체 치료 방법(methods of treatment with antibodies against bcma and cd3)
RS65943B1 (sr) 2019-11-11 2024-10-31 Amgen Res Munich Gmbh Režim doziranja anti-bcma agenasa
KR20220105664A (ko) 2019-11-26 2022-07-27 노파르티스 아게 Bcma 및 cd19에 결합하는 키메라 항원 수용체 및 이의 용도
TW202128769A (zh) * 2020-01-03 2021-08-01 大陸商信立泰（成都）生物技術有限公司 結合bcma的抗體及其用途
JP7456075B2 (ja) * 2020-01-03 2024-03-27 ビオシオン インコーポレイテッド 抗体結合ｂｃｍａ及びその使用
CN111234020B (zh) * 2020-01-23 2020-10-23 和铂医药(苏州)有限公司 一种bcma结合蛋白及其制备方法和应用
CN111171147B (zh) * 2020-02-11 2021-07-20 北京康普美特创新医药科技有限责任公司 一种抗补体c3分子的全人源单克隆抗体及应用
JP2023514224A (ja) * 2020-02-12 2023-04-05 ブリストル－マイヤーズ スクイブ カンパニー 自己免疫障害における抗ｂｃｍａ治療
WO2021173995A2 (en) 2020-02-27 2021-09-02 Novartis Ag Methods of making chimeric antigen receptor-expressing cells
US20230256017A1 (en) 2020-02-27 2023-08-17 Jennifer Brogdon Methods of making chimeric antigen receptor-expressing cells
CN116097096A (zh) * 2020-03-27 2023-05-09 印地安纳大学理事会 多发性骨髓瘤中的免疫治疗靶点及其鉴定方法
JP2023524068A (ja) 2020-04-30 2023-06-08 ブリストル－マイヤーズ スクイブ カンパニー サイトカイン関連有害事象を治療する方法
CA3185455A1 (en) 2020-06-11 2021-12-16 Novartis Ag Zbtb32 inhibitors and uses thereof
WO2022035793A1 (en) * 2020-08-10 2022-02-17 Precision Biosciences, Inc. Antibodies and fragments specific for b-cell maturation antigen and uses thereof
IL300489A (en) 2020-08-21 2023-04-01 Novartis Ag Compositions and methods for in vivo production of CAR expressing cells
US20240344058A1 (en) 2020-10-30 2024-10-17 Vor Biopharma Inc. Compositions and methods for bcma modification
CN113173991B (zh) * 2020-12-31 2023-03-28 北京艺妙神州医药科技有限公司 一种抗bcma的抗体及其应用
CA3214757A1 (en) 2021-04-08 2022-10-13 Andreas Loew Multifuntional molecules binding to tcr and uses thereof
CN118056008A (zh) 2021-04-27 2024-05-17 诺华股份有限公司 病毒载体生产系统
CN117321078A (zh) 2021-04-30 2023-12-29 豪夫迈·罗氏有限公司 针对用抗cd20/抗cd3双特异性抗体和抗cd79b抗体药物缀合物进行组合治疗的给药
US11931420B2 (en) 2021-04-30 2024-03-19 Celgene Corporation Combination therapies using an anti-BCMA antibody drug conjugate (ADC) in combination with a gamma secretase inhibitor (GSI)
BR112023024804A2 (pt) 2021-05-28 2024-02-15 Glaxosmithkline Ip Dev Ltd Terapias de combinação para tratar câncer
WO2023012669A2 (en) 2021-08-03 2023-02-09 Glaxosmithkline Intellectual Property Development Limited Biopharmaceutical compositions and stable isotope labeling peptide mapping method
CN116745325A (zh) * 2021-08-16 2023-09-12 上海优替济生生物医药有限公司 Bcma靶向抗体、嵌合抗原受体及其应用
WO2023020474A1 (en) * 2021-08-16 2023-02-23 Utc Therapeutics (Shanghai) Co., Ltd. Bcma targetting antibodies and uses thereof in cancer therapies
TW202323521A (zh) 2021-08-20 2023-06-16 瑞士商諾華公司 製備表現嵌合抗原受體的細胞之方法
EP4412713A1 (en) 2021-10-05 2024-08-14 GlaxoSmithKline Intellectual Property Development Ltd Combination therapies for treating cancer
CN118591560A (zh) 2022-01-25 2024-09-03 葛兰素史密斯克莱知识产权发展有限公司 癌症的组合疗法
AU2023320568A1 (en) 2022-08-05 2025-02-06 Juno Therapeutics, Inc. Chimeric antigen receptors specific for gprc5d and bcma
AU2023369684A1 (en) 2022-10-26 2025-04-17 Novartis Ag Lentiviral formulations
EP4630454A1 (en) 2022-12-05 2025-10-15 GlaxoSmithKline Intellectual Property Development Ltd Methods of treatment using b-cell maturation antigen antagonists
WO2024249954A1 (en) 2023-05-31 2024-12-05 Capstan Therapeutics, Inc. Lipid nanoparticle formulations and compositions
WO2025042742A1 (en) 2023-08-18 2025-02-27 Bristol-Myers Squibb Company Compositions comprising antibodies that bind bcma and cd3 and methods of treatment
WO2025059162A1 (en) 2023-09-11 2025-03-20 Dana-Farber Cancer Institute, Inc. Car-engager containing il-2 variants to enhance the functionality of car t cells
WO2025059362A1 (en) 2023-09-13 2025-03-20 Juno Therapeutics, Inc. Combination therapies with a cell therapy expressing a gprc5d-targeting car and related methods and uses
WO2025076127A1 (en) 2023-10-05 2025-04-10 Capstan Therapeutics, Inc. Constrained ionizable cationic lipids and lipid nanoparticles
WO2025076113A1 (en) 2023-10-05 2025-04-10 Capstan Therapeutics, Inc. Ionizable cationic lipids with conserved spacing and lipid nanoparticles
US20250115678A1 (en) * 2023-10-10 2025-04-10 Astrazeneca Ab T cell binding compositions and methods
US20250230251A1 (en) 2023-12-20 2025-07-17 Bristol-Myers Squibb Company Antibodies targeting il-18 receptor beta (il-18rb) and related methods

Family Cites Families (79)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4816567A (en) 1983-04-08 1989-03-28 Genentech, Inc. Recombinant immunoglobin preparations
US6410516B1 (en) 1986-01-09 2002-06-25 President & Fellows Of Harvard College Nuclear factors associated with transcriptional regulation
EP0307434B2 (en) 1987-03-18 1998-07-29 Scotgen Biopharmaceuticals, Inc. Altered antibodies
AU612370B2 (en) 1987-05-21 1991-07-11 Micromet Ag Targeted multifunctional proteins
US5204244A (en) 1987-10-27 1993-04-20 Oncogen Production of chimeric antibodies by homologous recombination
US5202238A (en) 1987-10-27 1993-04-13 Oncogen Production of chimeric antibodies by homologous recombination
US5273743A (en) 1990-03-09 1993-12-28 Hybritech Incorporated Trifunctional antibody-like compounds as a combined diagnostic and therapeutic agent
DE69232604T2 (de) 1992-11-04 2002-11-07 City Of Hope Duarte Antikörperkonstrukte
DK0672142T3 (da) 1992-12-04 2001-06-18 Medical Res Council Multivalente og multispecifikke bindingsproteiner samt fremstilling og anvendelse af disse
ATE204325T1 (de) 1993-04-29 2001-09-15 Unilever Nv Herstellung von antikörpern oder funktionstüchtig gemachten teilen davon, abgeleitet von schweren ketten von immunglobulinen von camelidae
US5885573A (en) 1993-06-01 1999-03-23 Arch Development Corporation Methods and materials for modulation of the immunosuppressive activity and toxicity of monoclonal antibodies
WO1996021012A1 (en) 1994-12-30 1996-07-11 Planet Biotechnology, Inc. Methods for producing immunoglobulins containing protection proteins in plants and their use
GB9501079D0 (en) 1995-01-19 1995-03-08 Bioinvent Int Ab Activation of T-cells
US5731168A (en) 1995-03-01 1998-03-24 Genentech, Inc. Method for making heteromultimeric polypeptides
EP0739981A1 (en) 1995-04-25 1996-10-30 Vrije Universiteit Brussel Variable fragments of immunoglobulins - use for therapeutic or veterinary purposes
EP0826696B1 (de) 1996-09-03 2002-05-29 GSF-Forschungszentrum für Umwelt und Gesundheit GmbH Verwendung bi-und trispezifischer Antikörper zur Induktion einer Tumorimmunität
CA2288992C (en) 1997-04-30 2012-06-12 Enzon, Inc. Single-chain antigen-binding proteins capable of glycosylation, production and uses thereof
US6194551B1 (en) 1998-04-02 2001-02-27 Genentech, Inc. Polypeptide variants
DE69942021D1 (de) 1998-04-20 2010-04-01 Glycart Biotechnology Ag Glykosylierungs-engineering von antikörpern zur verbesserung der antikörperabhängigen zellvermittelten zytotoxizität
GB9809951D0 (en) 1998-05-08 1998-07-08 Univ Cambridge Tech Binding molecules
US20020142000A1 (en) 1999-01-15 2002-10-03 Digan Mary Ellen Anti-CD3 immunotoxins and therapeutic uses therefor
IL144056A0 (en) 1999-01-15 2002-04-21 Genentech Inc Polypeptide variants with altered effector function
PT1176195E (pt) 1999-04-09 2013-07-18 Kyowa Hakko Kirin Co Ltd Processo para controlar a actividade de uma molécula funcional sob o ponto de vista imunológico
UA74798C2 (uk) 1999-10-06 2006-02-15 Байоджен Айдек Ма Інк. Спосіб лікування раку у ссавця за допомогою поліпептиду, що протидіє взаємодії april з його рецепторами
AU6232899A (en) 1999-10-06 2001-05-10 Campina Melkunie B.V. Use of transforming growth factor beta and growth factors in the treatment and prevention of diseases of the intestinal mucosa
EP1229125A4 (en) 1999-10-19 2005-06-01 Kyowa Hakko Kogyo Kk PROCESS FOR PREPARING A POLYPEPTIDE
ATE448301T1 (de) 2000-09-08 2009-11-15 Univ Zuerich Sammlung von proteinen mit sich wiederholenden sequenzen (repeat proteins), die repetitive sequenzmodule enthalten
WO2002030954A1 (fr) 2000-10-06 2002-04-18 Kyowa Hakko Kogyo Co., Ltd. Procede de purification d'un anticorps
EP3690043A1 (en) 2000-10-06 2020-08-05 Kyowa Kirin Co., Ltd. Antibody composition-producing cell
GB0029407D0 (en) 2000-12-01 2001-01-17 Affitech As Product
AU2002238052A1 (en) 2001-02-20 2002-09-04 Zymogenetics, Inc. Antibodies that bind both bcma and taci
EP2202243A3 (en) 2001-08-10 2012-08-08 Aberdeen University Antigen binding domains from fish
EP1293514B1 (en) 2001-09-14 2006-11-29 Affimed Therapeutics AG Multimeric single chain tandem Fv-antibodies
EP1314741B1 (en) 2001-11-14 2007-03-07 Affimed Therapeutics AG Bispecific anti-CD19 x anti-CD16 antibodies and uses thereof
US7317091B2 (en) 2002-03-01 2008-01-08 Xencor, Inc. Optimized Fc variants
GB0230201D0 (en) 2002-12-27 2003-02-05 Domantis Ltd Retargeting
ES2543734T3 (es) 2003-01-22 2015-08-21 Roche Glycart Ag Constructos de fusión y uso de los mismos para producir anticuerpos con mayor afinidad de unión al receptor de Fc y función efectora
DK1599504T3 (da) 2003-02-25 2015-03-09 Vaccibody As Modificeret antistof
AU2003259718A1 (en) 2003-08-07 2005-03-07 Epitomics, Inc. Methods for humanizing rabbit monoclonal antibodies
AU2004290070A1 (en) 2003-11-12 2005-05-26 Biogen Idec Ma Inc. Neonatal Fc receptor (FcRn)-binding polypeptide variants, dimeric Fc binding proteins and methods related thereto
US7235641B2 (en) 2003-12-22 2007-06-26 Micromet Ag Bispecific antibodies
DK2330121T3 (en) 2004-06-02 2014-12-15 Adalta Pty Ltd Binding moieties based on shark IgNar domains
RS50830B (sr) 2005-01-05 2010-08-31 F-Star Biotechnologische Forschungs-Und Entwicklungsges M.B.H. Sintetički domeni imunoglobulina sa vezujućim svojstvima izgrađenim u područjima molekula različitim od komplementarno određujućih područja
WO2006106905A1 (ja) 2005-03-31 2006-10-12 Chugai Seiyaku Kabushiki Kaisha 会合制御によるポリペプチド製造方法
EP1868650B1 (en) 2005-04-15 2018-10-03 MacroGenics, Inc. Covalent diabodies and uses thereof
EP1888649A2 (en) 2005-05-09 2008-02-20 GlycArt Biotechnology AG Antigen binding molecules having modified fc regions and altered binding to fc receptors
KR20080068004A (ko) 2005-08-15 2008-07-22 아라나 테라퓨틱스 리미티드 뉴 월드 영장류 구조형성영역을 가진 조작 항체
AU2006290433B2 (en) 2005-08-26 2012-06-07 Roche Glycart Ag Modified antigen binding molecules with altered cell signaling activity
AU2006299429B2 (en) 2005-10-03 2012-02-23 Xencor, Inc. Fc variants with optimized Fc receptor binding properties
JP5686953B2 (ja) 2005-10-11 2015-03-18 アムゲン リサーチ （ミュンヘン） ゲーエムベーハー 交差種特異的（ｃｒｏｓｓ−ｓｐｅｃｉｅｓ−ｓｐｅｃｉｆｉｃ）抗体を含む組成物および該組成物の使用
WO2007117600A2 (en) 2006-04-07 2007-10-18 Macrogenics, Inc. Combination therapy for treating autoimmune diseases
AU2007238034A1 (en) 2006-04-14 2007-10-25 Trubion Pharmaceuticals Inc. Binding proteins comprising immunoglobulin hinge and Fc regions having altered Fc effector functions
CN101802015B (zh) 2007-03-29 2015-05-06 根马布股份公司 双特异性抗体及其制造方法
AU2008234020B2 (en) 2007-04-03 2013-02-07 Amgen Research (Munich) Gmbh Cross-species-specific CD3-epsilon binding domain
CN101675077B (zh) 2007-04-03 2013-09-04 安进研发（慕尼黑）股份有限公司 跨种特异性的双特异性结合剂
MX2009010610A (es) 2007-04-03 2010-06-08 Micromet Ag Dominio de enlace especifico de especies cruzadas.
US20090162359A1 (en) 2007-12-21 2009-06-25 Christian Klein Bivalent, bispecific antibodies
US9266967B2 (en) 2007-12-21 2016-02-23 Hoffmann-La Roche, Inc. Bivalent, bispecific antibodies
KR20100097737A (ko) 2008-01-15 2010-09-03 에프. 호프만-라 로슈 아게 Ｃｃｒ５에 대한 어푸코실화된 항체 및 이의 용도
ES2523033T3 (es) 2008-03-18 2014-11-20 Seattle Genetics, Inc. Conjugados enlazadores del fármaco auriestatina
WO2009132058A2 (en) 2008-04-25 2009-10-29 Zymogenetics, Inc. Levels of bcma protein expression on b cells and use in diagnostic methods
HUE027499T2 (en) 2008-10-01 2016-10-28 Amgen Res Munich Gmbh Bispecific single chain antibodies with specificity for high molecular weight target antigens
EP3375790A1 (en) 2008-10-01 2018-09-19 Amgen Research (Munich) GmbH Cross-species-specific single domain bispecific single chain antibody
SI2356153T1 (sl) 2008-10-01 2016-07-29 Amgen Research (Munich) Gmbh Bispecifično enoverižno protitelo, specifično za križane vrste
JP5746040B2 (ja) 2008-12-03 2015-07-08 ゲンマブ エー／エス 定常領域の中に改変を有する抗体変種
NZ612647A (en) * 2009-03-10 2015-03-27 Biogen Idec Inc Anti-bcma antibodies
TWI409079B (zh) 2009-08-14 2013-09-21 Roche Glycart Ag 非典型岩藻醣化ｃｄ２０抗體與苯達莫斯汀（ｂｅｎｄａｍｕｓｔｉｎｅ）之組合療法
EP3974453A3 (en) * 2010-11-16 2022-08-03 Amgen Inc. Agents and methods for treating diseases that correlate with bcma expression
KR101614195B1 (ko) 2011-03-29 2016-04-20 로슈 글리카트 아게 항체 Fc 변이체
US20130101599A1 (en) 2011-04-21 2013-04-25 Boehringer Ingelheim International Gmbh Bcma-based stratification and therapy for multiple myeloma patients
CN106279418A (zh) 2011-05-27 2017-01-04 葛兰素集团有限公司 Bcma（cd269/tnfrsf17）结合蛋白
TWI679212B (zh) * 2011-11-15 2019-12-11 美商安進股份有限公司 針對ｂｃｍａ之e3以及ｃｄ３的結合分子
NZ700362A (en) 2012-04-11 2016-09-30 Us Health Chimeric antigen receptors targeting b-cell maturation antigen
WO2014122143A1 (en) * 2013-02-05 2014-08-14 Engmab Ag Method for the selection of antibodies against bcma
AR095374A1 (es) 2013-03-15 2015-10-14 Amgen Res Munich Gmbh Moléculas de unión para bcma y cd3
GB201317929D0 (en) 2013-10-10 2013-11-27 Ucl Business Plc Chimeric antigen receptor
US10287354B2 (en) 2013-12-20 2019-05-14 Novartis Ag Regulatable chimeric antigen receptor
US10239948B2 (en) 2013-12-20 2019-03-26 Cellectis Method of engineering multi-input signal sensitive T cell for immunotherapy
AU2015360845B2 (en) 2014-12-12 2020-11-26 2Seventy Bio, Inc. BCMA chimeric antigen receptors

Also Published As

Publication number Publication date
JP2018532766A (ja) 2018-11-08
HK1249114A1 (en) 2018-10-26
CN108350073A (zh) 2018-07-31
IL257233B (en) 2021-06-30
DK3331910T3 (da) 2020-03-16
CY1122804T1 (el) 2021-05-05
PT3331910T (pt) 2020-03-24
MX377710B (es) 2025-03-11
CL2020002801A1 (es) 2021-02-19
ECSP18007905A (es) 2018-10-31
MX2018001398A (es) 2018-05-28
JP2020109117A (ja) 2020-07-16
HUE048939T2 (hu) 2020-09-28
EA201890441A1 (ru) 2018-07-31
EA036975B1 (ru) 2021-01-21
CL2018000281A1 (es) 2018-11-09
JP6682632B2 (ja) 2020-04-15
KR102717307B1 (ko) 2024-10-15
PL3331910T3 (pl) 2020-05-18
EP3670535A1 (en) 2020-06-24
EA202092435A3 (ru) 2021-06-30
US20200283545A1 (en) 2020-09-10
ES2777602T3 (es) 2020-08-05
SMT202000139T1 (it) 2020-05-08
HRP20200390T1 (hr) 2020-06-12
EP3331910A1 (en) 2018-06-13
EA202092435A2 (ru) 2021-02-26
EP3331910B1 (en) 2019-12-11
ZA201800435B (en) 2018-12-19
IL257233A (en) 2018-03-29
CL2020001048A1 (es) 2020-08-28
SI3331910T1 (sl) 2020-07-31
LT3331910T (lt) 2020-03-25
BR112018001955A2 (pt) 2018-09-18
CA2992797A1 (en) 2017-02-09
KR20180042271A (ko) 2018-04-25
AU2016302881A1 (en) 2018-02-08
BR112018001955B1 (pt) 2021-05-11
AU2016302881B2 (en) 2022-09-15
JP6903188B2 (ja) 2021-07-14
SA518390854B1 (ar) 2020-12-07
US20230322957A1 (en) 2023-10-12
CN108350073B (zh) 2022-03-18
SG10202007177XA (en) 2020-09-29
CO2018001149A2 (es) 2018-07-10
WO2017021450A1 (en) 2017-02-09
RS60030B1 (sr) 2020-04-30
US10683369B2 (en) 2020-06-16
US20190352427A1 (en) 2019-11-21
NZ739252A (en) 2023-12-22

Similar Documents

Publication Publication Date Title
MX2020009649A (es) Anticuerpos monoclonales contra bcma.
ZA202107931B (en) Anti-tau antibodies and methods of use
MX2021006235A (es) Anticuerpos anti-tigit, anticuerpos anti-pvrig y combinaciones de estos.
PH12016501763A1 (en) Multispecific antibodies
PH12017502180A1 (en) Tau-binding antibodies
PH12018502225A1 (en) Anti-il-33 antibodies, compositions, methods and uses thereof
PH12018500711A1 (en) Anti-pd1 antibodies and methods of use
PH12017500861A1 (en) Anti-interleukin-33 antibodies and uses thereof
PH12017500877B1 (en) ANTI-CD79b ANTIBODIES AND METHODS OF USE
MX2019007021A (es) Anticuerpos il-11ra.
MX2017003478A (es) Anticuerpos anti-fgfr2/3 y metodos para su uso.
MY193677A (en) Tau-binding antibodies
SG10201909716RA (en) Modified j-chain
MX2016015162A (es) Anticuerpos anti - gpc3 e inmunoconjugados.
TW201613963A (en) Anti-JAGGED1 antibodies and methods of use
ZA201703510B (en) Antibodies, uses & methods
MX2016004853A (es) Metodos de uso de anticuerpos anti-ly6e.
PH12018550160B1 (en) NEW ANTI-SIRPa ANTIBODIES AND THEIR THERAPEUTIC APPLICATIONS
MX2018001465A (es) Nuevos anticuerpos anti-gpvi humana y sus usos.
MX2016016233A (es) Anticuerpos anti-lgr5 y sus usos.
EA201792492A1 (ru) Aml-антигены и их применение
NZ744340A (en) Anti-jagged1 antibodies and methods of use